Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 12, 2023

SELL
$3.08 - $7.39 $33,809 - $81,120
-10,977 Reduced 9.31%
106,938 $370,000
Q4 2022

Feb 08, 2023

BUY
$3.22 - $4.86 $14,931 - $22,535
4,637 Added 4.09%
117,915 $492,000
Q3 2022

Nov 09, 2022

BUY
$4.01 - $12.34 $101,689 - $312,930
25,359 Added 28.84%
113,278 $454,000
Q2 2022

Aug 10, 2022

BUY
$8.27 - $18.43 $288,656 - $643,280
34,904 Added 65.84%
87,919 $993,000
Q1 2022

May 04, 2022

SELL
$12.54 - $46.93 $1.25 Million - $4.69 Million
-99,887 Reduced 65.33%
53,015 $861,000
Q4 2021

Feb 10, 2022

BUY
$45.28 - $74.5 $4.39 Million - $7.22 Million
96,859 Added 172.83%
152,902 $7.25 Million
Q3 2021

Nov 10, 2021

BUY
$57.18 - $84.43 $3.2 Million - $4.73 Million
56,043 New
56,043 $4.06 Million

Others Institutions Holding IMAB

About I-Mab


  • Ticker IMAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 83,098,800
  • Market Cap $130M
  • Description
  • I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...
More about IMAB
Track This Portfolio

Track California Public Employees Retirement System Portfolio

Follow California Public Employees Retirement System and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of California Public Employees Retirement System, based on Form 13F filings with the SEC.

News

Stay updated on California Public Employees Retirement System with notifications on news.